The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition. By Dani Blum I’ve reported on Ozempic since 2022. New research shows ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...